This study evaluates the efficacy of a new florfenicol-based drug, both in vitro and in vivo, in Nile tilapia (Oreochromis niloticus) against pathogens commonly found in fish farming and its withdrawal period. The drug’s efficacy was tested using prophylactic, metaphylactic, and therapeutic approaches against Streptococcus agalactiae (serotypes Ib and III) and Francisella orientalis. The minimum inhibitory concentration of florfenicol was 4, 5, and 128 μg/mL for the different pathogens. Fish mortality was lower in the prophylactic treatment compared to the metaphylactic and therapeutic treatments for S. agalactiae. No difference in mortality was observed for F. orientalis across treatments. Mild to moderate lesions suggestive of intoxication were observed, mainly in the liver of fish treated with overdoses or exposed to low temperatures. Florfenicol reduced mortality rates, especially with early treatment (metaphylactic), in fish experimentally challenged with the pathogens. Moreover, prophylactic antimicrobial use is not recommended, as it promotes the selection of multidrug-resistant bacterial strains. Additionally, the residual concentration of the drug in muscle tissue lasted for a shorter period than that recommended by the manufacturer, and at lower concentrations than required by national and international legislation.

This study evaluated the effects of supplementing the diet of juvenile Nile tilapia (Oreochromis niloticus), which weighs approximately 20 g, with a blend of monoglycerides (glycerides linked to a fatty acid molecule) for 20 days during a pre-experimental challenge via the intraperitoneal route (IP). Growth performance, immunological parameters, intestinal microbiota, tissue damage, and resistance against the pathogens Streptococcus agalactiae serotypes Ib and III and Francisella orientalis were evaluated. The experimental design included a negative control (NC), a product control (NPC), a positive control for each pathogen (PC), and three groups treated with different doses (0.15, 0.25, and 0.5%). After the challenge, mortality was significantly lower in the groups treated and challenged with S. agalactiae. The treated groups showed better weight gain and food conversion rates. Innate immunity parameters showed no differences between treatments, and there was no good stimulation of diversity in the intestinal microbiota. However, in treated groups, there was a reduction in opportunistic bacteria that could cause secondary infections and increased the presence of beneficial bacteria in the intestinal tract. In this way, it is possible to validate the beneficial effects of monoglycerides as a nutritional additive for tilapia farms against streptoccocosis.